专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明专利

IL241702D0 Process for preparation of mixtures of polypeptides using purified hydrobromic acid 未知
公开(公告)号：IL241702D0
公开(公告)日：2015-11-30
申请号：IL24170215
申请日：2015-09-17
申请人： TEVA PHARMA , BEN ZION DOLITZKY
IPC分类号： C07K20060101
摘要： The Subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.

3. 发明专利

IL180351D0 METHOD FOR REDUCING RESIDUAL ALCOHOLS IN CRYSTALLINE VALACYCLOVER HYDROCHLORIDE 未知
公开(公告)号：IL180351D0
公开(公告)日：2007-06-03
申请号：IL18035106
申请日：2006-12-26
申请人： TEVA PHARMA , BEN ZION DOLITZKY , LGOR LIFSHITZ
IPC分类号： C07D20100101 , C07D473/00 , C07D473/18

4. 发明授权

US07560100B2 Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases 有权
标题翻译：多肽混合物，含有它们的组合物及其制备方法，用于治疗神经变性疾病
公开(公告)号：US07560100B2
公开(公告)日：2009-07-14
申请号：US11223408
申请日：2005-09-09
申请人： Irit Pinchasi , Ben-Zion Dolitzky , Anton Frenkel , Michal Schwartz , Ruth Arnon , Rina Aharoni
发明人： Irit Pinchasi , Ben-Zion Dolitzky , Anton Frenkel , Michal Schwartz , Ruth Arnon , Rina Aharoni
IPC分类号： A61K31/74
CPC分类号： C07K14/001 , A61K38/02
摘要： The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.
摘要翻译：本发明提供包含多肽混合物的组合物，其中每个多肽（a）是L-谷氨酸，L-丙氨酸，L-酪氨酸和L-赖氨酸的氨基酸的共聚物，和（b）可以在形式的药学上可接受的盐; 并且其中在所述混合物（i）中，所述多肽的平均分子量范围为13,500至18,500道尔顿，（ii）13％至38％的多肽具有二乙酰胺基团而不是存在于其一端的羧基，以及（iii）68％的多肽具有7,000至41,000道尔顿的分子量。在一个实施方式中，平均分子量为16,000道尔顿。本发明还提供了治疗患有神经变性疾病的人类受试者的方法，包括向人类受试者施用治疗有效量的任何所公开的组合物，从而治疗人受试者。

5. 发明申请

US20090149497A1 POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE 审中-公开
标题翻译： FEXOFENADINE HYDROCHLORIDE的聚合物
公开(公告)号：US20090149497A1
公开(公告)日：2009-06-11
申请号：US12207372
申请日：2008-09-09
申请人： Ben-Zion DOLITZKY , Shlomit Wizel , Barnaba Krochmal , Dov Diller , Irwin Gross
发明人： Ben-Zion DOLITZKY , Shlomit Wizel , Barnaba Krochmal , Dov Diller , Irwin Gross
IPC分类号： A61K31/445 , C07D211/34
CPC分类号： C07D211/22
摘要： The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is anhydrous, but can be crystallized as a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.
摘要翻译：本发明提供盐酸非索非那定形式V，VI和VIII至XV的新型结晶形式及其制备和制备盐酸非索非那定的无定形形式和其它结晶形式的方法。形式XIV和XV是乙酸乙酯的溶剂化物，而形式IX是无水的，但可以结晶为MTBE或环己烷的溶剂合物。这些形式可用于给予人类和动物以减轻组胺引起的症状。本发明还提供了新的结晶形式的药物组合物。

6. 发明授权

US07504504B2 Methods of preparing aripiprazole crystalline forms 有权
公开(公告)号：US07504504B2
公开(公告)日：2009-03-17
申请号：US11015068
申请日：2004-12-16
申请人： Judith Aronhime , Ben-Zion Dolitzky , Eran Luvchick , Jean Hildesheim , Hagit Eisen-Nevo , Reuven Izsak
发明人： Judith Aronhime , Ben-Zion Dolitzky , Eran Luvchick , Jean Hildesheim , Hagit Eisen-Nevo , Reuven Izsak
IPC分类号： C07D401/12
CPC分类号： C07D215/227 , A61K31/496
摘要： The invention encompasses aripiprazole crystalline forms, methods of preparing the same, and pharmaceutical compositions having aripiprazole crystalline forms.

7. 发明申请

US20090069598A1 Solid and crystalline ibandronic acid 审中-公开
标题翻译：固体和结晶伊班膦酸
公开(公告)号：US20090069598A1
公开(公告)日：2009-03-12
申请号：US12288025
申请日：2008-10-15
申请人： Thomas Bayer , Ben-Zion Dolitzky , Revital Lifshitz-Liron , Inna Perutski , Michael Pinchasov
发明人： Thomas Bayer , Ben-Zion Dolitzky , Revital Lifshitz-Liron , Inna Perutski , Michael Pinchasov
IPC分类号： C07F9/28
CPC分类号： C07F9/3873
摘要： Provided are novel crystalline forms of ibandronic acid, physical data, methods for their preparation, and uses therefor. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form.
摘要翻译：提供了ibandronic酸的新型结晶形式，物理数据，其制备方法及其用途。还提供了用于纯化和测定任何结晶形式的伊班膦酸的方法。

8. 发明授权

US07358390B2 Polymorphic forms of nateglinide 失效
标题翻译：那格列奈的多形态
公开(公告)号：US07358390B2
公开(公告)日：2008-04-15
申请号：US10623290
申请日：2003-07-18
申请人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
发明人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
IPC分类号： C07C229/00
CPC分类号： C07C233/63 , A61K31/198 , C07B2200/13 , C07C2601/14
摘要： Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.
摘要翻译：提供那格列奈的结晶形式，标记为A，C，D，F，G，I，J，K，L，M，N，O，P，Q，T，U，V，Y，α，β，，δ，ε，σ，θ和Ω，它们的制备方法和制备那格列奈的其它结晶形式的方法。还提供了它们的药物制剂和给药方法。

9. 发明授权

US07256195B2 Preparation of risperidone 失效
标题翻译：制备利培酮
公开(公告)号：US07256195B2
公开(公告)日：2007-08-14
申请号：US10669272
申请日：2003-09-23
申请人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime
发明人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime
IPC分类号： A61K31/5191 , A61P25/18 , C07D239/70
CPC分类号： C07D471/04
摘要： The present invention is directed to the novel forms of risperidone, designated Form A, Form B and Form E. Methods for their preparation are also disclosed. The present invention also relates to processes for making risperidone. Pharmaceutical compositions containing the new forms of risperidone and methods of using them are also disclosed.
摘要翻译：本发明涉及利培酮的新型，称为A型，B型和E型。其制备方法也公开。本发明还涉及制造利培酮的方法。还公开了含有新型利培酮及其使用方法的药物组合物。

10. 发明申请

US20070054857A1 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof 审中-公开
标题翻译：多肽的组合物，含有的组合物及其制备方法及其用途
公开(公告)号：US20070054857A1
公开(公告)日：2007-03-08
申请号：US11541263
申请日：2006-09-29
申请人： Irit Pinchasi , Ben-Zion Dolitzky , Anton Frenkel , Michal Schwartz , Ruth Arnon , Rina Aharoni
发明人： Irit Pinchasi , Ben-Zion Dolitzky , Anton Frenkel , Michal Schwartz , Ruth Arnon , Rina Aharoni
IPC分类号： A61K38/16
CPC分类号： C07K14/001 , A61K38/02
摘要： The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.
摘要翻译：本发明提供包含多肽混合物的组合物，其中每个多肽（a）是L-谷氨酸，L-丙氨酸，L-酪氨酸和L-赖氨酸的氨基酸的共聚物，和（b）可以在形式的药学上可接受的盐; 并且其中在所述混合物（i）中，所述多肽的平均分子量范围为13,500至18,500道尔顿，（ii）13％至38％的多肽具有二乙酰胺基团而不是存在于其一端的羧基，以及（iii）68％的多肽具有7,000至41,000道尔顿的分子量。在一个实施方案中，平均分子量为16,000道尔顿，其制备及其用途的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式